Jiangsu Aidi Pharmaceutical Group Co., Ltd. was founded in 2009 and listed on the STAR Market of the Shanghai Stock Exchange in 2020, with the stock code 688488.SH. The company takes anti-AIDS drugs as its core development area, while leveraging its competitive edge in the field of human protein. Guided by the unmet clinical diagnosis and treatment needs in China, it actively explores, researches and develops, and sells innovative drugs.

Aidi Pharmaceutical is committed to building a complete pipeline for the research and development of new antiviral drugs for HIV, and has core technological advantages and product first-mover advantages in this field. It strives to provide patients with more comprehensive and diverse drug options, continuously meeting the urgent needs of domestic AIDS treatment upgrades, and striving to become a leader in the field of AIDS treatment. Meanwhile, the company is constantly consolidating its resource advantages in the field of human protein and actively laying out the upstream and downstream industrial ecosystem in this field. The company will continue to invest in the fields of HIV antiviral and human protein, constantly enhance its commercial operation capabilities, and gradually build an international industrial pattern that is based in China and oriented towards the world. Aidea: "A" symbolizes leading and being top-notch, while "idea" symbolizes creativity and conception. "Aidea" stands for leading innovation and dreams. The company has always adhered to the value concept of "integrity, responsibility, innovation and perseverance", aiming high, being pragmatic and enterprising, and striving to realize the lofty vision of "becoming a respected and outstanding pharmaceutical enterprise"!